Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia

INCLUSION CRITERIA: * Signed Informed Consent. * Histologically confirmed relapsed or refractory CD20 positive FL grade 1-3a and 1 or more clearly demarcated lesions with a largest diameter = 1.5 cm, or CD5, CD19, CD20 and CD23 positive relapse or refractory CLL. * Subjects must have adequate blood, liver, and kidney function. * Subjects who passed the provided periods from the last anti-cancer treatments at screening * ECOG Performance Status of 0-2 * Life expectancy more than 24 weeks at screening EXCLUSION CRITERIA: * Current and past malignancy other than FL and CLL within 5 years prior to screening. * Known Richter's transformation * Previous autologous stem cell transplantation within 24 weeks prior to screening * Previous allogeneic stem cell transplantation * Known CNS involvement * History of significant cerebrovascular disease * Current cardiac disease requiring medical treatment * Chronic or ongoing active infectious disease requiring systemic treatment * Patients with pleural effusion or ascites detectable by physical examination * Positive serology test for any of HBsAg, anti-HBc or anti-HCV * Known HIV positive * Pregnant or lactating women * Women of childbearing potential and male patients not willing to use adequate contraception